Brand name: Lifyorli Generic name: relacorilant Manufacturer: Corcept Therapeutics Inc. Approval date: March 25, 2026 FDA approved Lifyorli (relacorilant), an
Pfizer and Valneva announced positive topline results from the phase 3 VALOR trial of their investigational Lyme disease vaccine candidate,
A meta-analysis found no evidence that hormonal contraception increases the prevalence of idiopathic intracranial hypertension (IIH). Investigators pooled data from
Abstract Background: Craniospinal irradiation (CSI) has a decisive impact on the control of pediatric tumors with a high probability of
Abstract Lymphoepithelioma-like gastric cancer (LELGC) is a rare subtype of gastric carcinoma associated with Epstein-Barr virus infection. Although it can